The U.S. Senate easily passed a bill allowing for drug reimports. Supporters harshly criticized drug makers for pushing the world's highest prices in the United States while critics fell back on their position that regulators couldn't guarantee the safety of imported drugs. White House advisers said they would back a veto of any reimportation bill, which has been repeatedly rejected by top federal officials.
Reimportation has been a big issue in biotechnology. With drug developers dependent on the U.S. market for the biggest slice of their profits, developers believe that any move to crimp drug sales in the U.S. could blunt the value of new therapies.
- read the Washington Post report